Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/118941
How much fat loss is needed for lipoatrophy to become clinically evident?
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The objective of this study was to evaluate how much limb fat is needed to be lost for lipoatrophy to become clinically evident. Antiretroviral drug-naive patients from a randomized trial comparing stavudine or abacavir plus lamivudine and efavirenz, who had subjective assessment to detect clinically evident lipoatrophy (standardized questionnaire) and objective measurements of limb fat (dual X-ray absorptiometry) at baseline, 48 weeks, and 96 weeks were included. ROC curves were used to assess the sensitivity and specificity of several cut-off values of absolute and percent limb fat loss for diagnosing lipoatrophy. Of 54 patients included, 13 (24%) had subjective lipoatrophy at 96 weeks. After 96 weeks, median limb fat change was −2.3 kg (interquartile range: −5.2, +0.2) and 0.4 kg (interquartile range: −7.2, +3.4) in patients with and without lipoatrophy, respectively. Median percent limb fat change was −45.5% (interquartile range: −78.0, +3.7) and 5.5% (interquartile range: −62.8, +95.6), respectively. The cut-off values of absolute and percent limb fat loss showing the best sensitivity and specificity values were −1.5 kg (sensitivity, 77%; specificity, 76%) and −30% (sensitivity, 85%; specificity, 73%). At least 30% limb fat is needed to be lost in HIV-infected patients for lipoatrophy to become clinically evident.
Matèries
Matèries (anglès)
Citació
Citació
PODZAMCZER PALTER, Daniel, FERRER, Elena, MARTÍNEZ CHAMORRO, Esteban josé, RÍO, Luis del, ROSALES, Joaquín, CURTO, J. j. (jorge juan), RIBERA, Esteban, BARRUFET, Pilar m., LLIBRE, Josep maría, ARANDA, Miquel, ABCDE Study Team. How much fat loss is needed for lipoatrophy to become clinically evident?. _Aids Research and Human Retroviruses_. 2009. Vol. 25, núm. 6, pàgs. 563-567. [consulta: 23 de gener de 2026]. ISSN: 0889-2229. [Disponible a: https://hdl.handle.net/2445/118941]